Casting-type calcifications on the mammogram suggest a higher probability of early relapse and death among high-risk breast cancer patients

A retrospective analysis of the relation between the presence of casting-type calcifications on the mammogram and the prognosis of breast cancer was performed. The mammographic tumor features and other characteristics (invasive tumor size, histological tumor type, grade, nodal, hormone receptor and HER2 status, presence of lymphovascular invasion) of 55 high-risk breast cancers were studied. After a median follow-up time of 29.1 months, the median relapse-free survival and overall survival times among breast cancer patients with tumors associated with casting calcifications were 26.6 and 29.6 months, respectively. The corresponding parameters among patients with tumors not accompanied by casting calcifications were 54.4 and >58.5 months, respectively. Significant associations were found between the presence of casting calcifications and the risks of relapse (HR = 3.048, 95% CI: 1.116–8.323, p = 0.030) or death (HR = 3.504, 95% CI: 1.074–11.427, p = 0.038). Positive associations were found between casting calcifications and ER/PR negativity (p = 0.015 and p = 0.003, respectively) and HER2 overexpression (p = 0.019). Our findings support the theory that breast tumors associated with casting-type calcifications at mammography comprise a disease entity which exhibits significantly more aggressive behavior and a poorer outcome than do cancers with other mammographic tumor features.

[1]  K. Shen,et al.  Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .

[2]  I. Ellis,et al.  Is the presence of mammographic comedo calcification really a prognostic factor for small screen-detected invasive breast cancers? , 2003, Clinical radiology.

[3]  J. O’Shaughnessy Extending survival with chemotherapy in metastatic breast cancer. , 2005, The oncologist.

[4]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[5]  L. Tabár,et al.  A new era in the diagnosis of breast cancer. , 2000, Surgical oncology clinics of North America.

[6]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[7]  B. Cady,et al.  Casting-type calcifications with invasion and high-grade ductal carcinoma in situ: a more aggressive disease? , 2003, Archives of surgery.

[8]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  John R. Mackey,et al.  Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. , 2009 .

[10]  M. Eisenberger,et al.  Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. , 2005, The oncologist.

[11]  R. Given-Wilson,et al.  Mammographic casting-type calcification associated with small screen-detected invasive breast cancers: is this a reliable prognostic indicator? , 2004, Clinical radiology.

[12]  Yueh-Hsia Chiu,et al.  Mammographic tumor features can predict long‐term outcomes reliably in women with 1–14‐mm invasive breast carcinoma , 2004, Cancer.

[13]  A. Purushotham,et al.  Predicting local recurrence by correlating pre-operative mammographic findings with pathological risk factors in patients with breast cancer. , 1995, The British journal of radiology.

[14]  Philip Smith,et al.  Evaluation of infiltrating ductal carcinomas with a DCIS component: correlation of the histologic type of the in situ component with grade of the infiltrating component. , 1994, Seminars in diagnostic pathology.

[15]  A. Purushotham,et al.  Preoperative mammographic features predict clinicopathological risk factors for the development of local recurrence in breast cancer. , 2000, Breast.

[16]  K. Byth,et al.  Histopathologic indicators of breast cancer biology: insights from population mammographic screening , 2005, British Journal of Cancer.

[17]  青儀 健二郎,et al.  What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及 , 2006 .

[18]  E. Thurfjell,et al.  Mammographic finding as predictor of survival in 1–9mm invasive breast cancers. Worse prognosis for cases presenting as calcifications alone , 2001, Breast Cancer Research and Treatment.

[19]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[20]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[21]  M. V. Vijver Gene-Expression Profiling and the Future of Adjuvant Therapy , 2005 .

[22]  K. Boda,et al.  Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy Is Well Tolerated and Safe in High-Risk Early Breast Cancer , 2005, Oncology.

[23]  I. Fentiman,et al.  Ductal in situ Component and Prognosis in Invasive Mammary Carcinoma , 2004, Breast Cancer Research and Treatment.

[24]  Stephen W Duffy,et al.  A novel method for prediction of long-term outcome of women with T1a, T1b, and 10–14 mm invasive breast cancers: a prospective study , 2000, The Lancet.

[25]  P. Ravdin,et al.  Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.